Compare Acadia Healthcare Company Inc (ACHC) vs Freeport-McMoRan Inc (FCX) Price & Performance

ACHC trades at $31.70, up 1.93% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $0.38, beating estimates, but faces negative net income margins and ongoing litigation concerns. Revenue trends show modest growth to $3.4B in 2026, while cash flow from operations improved year-over-year.

Outlook is mixed: strong analyst buy consensus (68%) and a $36 price target suggest upside, but profitability challenges and legal risks weigh on sentiment. Investment opportunity hinges on execution of turnaround strategy and demand growth in behavioral health, balanced against operational and litigation headwinds.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.